10x Genomics, Inc.

NasdaqGS:TXG Rapporto sulle azioni

Cap. di mercato: US$2.1b

10x Genomics Gestione

Gestione criteri di controllo 3/4

10x Genomics Il CEO è Serge Saxonov, nominato in Jul2012, e ha un mandato di 12.33 anni. la retribuzione annua totale è $ 8.29M, composta da 6.6% di stipendio e 93.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 3.33% delle azioni della società, per un valore di $ 69.80M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 5.4 anni.

Informazioni chiave

Serge Saxonov

Amministratore delegato

US$8.3m

Compenso totale

Percentuale dello stipendio del CEO6.6%
Mandato del CEO12.3yrs
Proprietà del CEO3.3%
Durata media del management2.8yrs
Durata media del Consiglio di amministrazione5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Nov 01
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

10x Genomics: Deciphering The Preliminary Q3 Earnings

Oct 12

The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

Oct 11
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

10x Genomics Is Still A Long Way From Profitability

Oct 03

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Serge Saxonov rispetto agli utili di 10x Genomics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$183m

Jun 30 2024n/an/a

-US$240m

Mar 31 2024n/an/a

-US$264m

Dec 31 2023US$8mUS$545k

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Sep 30 2019n/an/a

-US$100m

Jun 30 2019n/an/a

-US$105m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$1mUS$366k

-US$112m

Compensazione vs Mercato: La retribuzione totale di Serge ($USD 8.29M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.54M ).

Compensazione vs guadagni: La retribuzione di Serge è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Serge Saxonov (47 yo)

12.3yrs

Mandato

US$8,286,050

Compensazione

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Serge Saxonov
Co-Founder12.3yrsUS$8.29m3.33%
$ 69.8m
Benjamin Hindson
Co-Founder12.3yrsUS$4.43m2.68%
$ 56.2m
Eric Whitaker
Chief Legal Officer7.3yrsUS$3.88m0.12%
$ 2.5m
Adam Taich
CFO, Treasurerless than a yearNessun datoNessun dato
Jim Goodrich
Chief of Global Operationsless than a yearNessun datoNessun dato
Michael Schnall-Levin
Founding Scientist & CTO2.8yrsNessun datoNessun dato
Alexander Wong
Chief Information Officerless than a yearNessun datoNessun dato
Cassie Corneau
Manager of Investor Relations & Strategic Financeno dataNessun datoNessun dato
Rebecca Port
Chief People Officer3.8yrsNessun datoNessun dato
Mennah Moustafa
Chief Commercial Officerless than a yearNessun datoNessun dato
Jens Durruthy
Associate Director of Product Managementno dataNessun datoNessun dato

2.8yrs

Durata media

48.5yo

Età media

Gestione esperta: Il team dirigenziale di TXG è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Serge Saxonov
Co-Founder12.3yrsUS$8.29m3.33%
$ 69.8m
Benjamin Hindson
Co-Founder12.3yrsUS$4.43m2.68%
$ 56.2m
Kimberly Popovits
Independent Director4.7yrsUS$338.71k0.0038%
$ 80.0k
John Stuelpnagel
Independent Chairman11.3yrsUS$403.59k2.02%
$ 42.3m
Shehnaaz Suliman
Independent Director5.3yrsUS$336.39k0.0038%
$ 80.0k
Alan Mateo
Directorless than a yearNessun datoNessun dato
Sridhar Kosaraju
Independent Director5.6yrsUS$346.39k0.029%
$ 614.6k
Sarah Polonius-Teichmann
Directorless than a yearNessun datoNessun dato

5.4yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TXG sono considerati esperti (durata media dell'incarico 5.4 anni).